TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · major macro event coming up
RARE

Ultragenyx

Healthcare · Biotechnology

14.50$ -1.8% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RARE
Line item 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
– +628.1% -32.5% +231.9% +182.7% -3.4% -9.2% +46.6% +57.8% +55.0% -13.5% +1.5% -3.5% +0.8% +1.9%
– +689.2% -36.1% +239.5% +140.1% +10.6% -50.9% +113.7% +62.9% +52.2% -33.9% +3.2% -17.2% +11.6% +16.4%
– +709.7% -91.4% +227.5% +284.7% +72.2% -37.6% +12.9% +282.2% +64.6% -56.9% -56.8% +60.7% -18.7% +149.8%
– +709.7% -38.1% +251.3% +133.1% +14.0% -50.9% +88.0% +64.3% +59.1% -38.4% +1.0% -22.8% +5.7% +13.6%
– – – – – – – +146.3% +157.8% -29.7% +92.4% -9.0% +81.5% +66.0% +30.5%
– – – – – – – +833.3% +63.4% +13.0% +24.4% +64.9% +26.9% +32.5% +15.5%
– +79.4% -2.7% +128.9% +143.1% +131.3% +28.0% -8.2% +272.5% -1.6% +92.1% +83.9% – – –
– – – – – – – +0.0% +0.0% +0.0% +0.0% +0.0% +0.0% +0.0% -0.9%
– – – – – – – -8.7% -0.2% +1.6% -0.2% +22.4% +3.9% +7.2% -1.3%
– +167.6% +139.9% +36.5% +118.7% +134.0% +61.0% +3.1% +335.4% +25.6% -0.9% +98.9% +1.9% +2.1% +29.3%
– +219.1% +85.7% +111.4% +123.0% +115.8% +17.8% +5.2% +38.2% +83.6% -4.3% +44.0% +7.4% +22.7% +11.6%
– – – – – – – – – +24.1% +23.3% +6.4% +6.9% -18.2% +686.6%
– +250.9% +19.8% +238.0% -39.4% +82.3% +65.7% +38.1% +4.9% +0.4% +32.6% +152.5% -2.7% -8.0% -20.0%
– +139.8% +560.0% -100.0% – – – – – – – – – – –
– +692.4% -40.6% +269.1% +187.2% -10.8% -19.1% +58.8% +7.4% +76.6% -20.1% -61.8% -21.9% -7.3% -131.3%
– – – – – – – – – – – – – – –
– +0.0% +26.0% -1.1% +27.9% +7.6% +7.2% +17.2% +13.7% +7.5% +11.4% +3.1% +5.2% +23.1% +8.9%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?